Second, frequent vMRI scans during trials with the BACE inhibitor verubecestat in Alzheimer’s disease revealed a transient decrease in hippocampal volume loss relative to placebo immediately following treatment initiation (0–3 months) but subsequently no difference from placebo over the remaining trial period (3–18 months) [187]. Here, BACE1 is linked to early-onset autosomal dominant Alzheimer disease.